Article

Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population.

Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
AIDS patient care and STDs (impact factor: 2.68). 10/2009; 23(11):925-9. DOI:10.1089/apc.2009.0099 pp.925-9
Source: PubMed

ABSTRACT This retrospective cohort study of HIV/hepatitis C virus (HCV) coinfected patients evaluated time trends and rates of HCV evaluation for patients seen between January 1, 1997 and October 30, 2004. Survival analysis and Cox proportional hazards modeling were used to describe the time to evaluation and covariates associated with this outcome. Patients were predominantly white and male. Of 248 eligible patients, 108 (44%) were evaluated for HCV treatment. The median time to evaluation was 2.98 years. Of 108 evaluated, 17 (16%) received at least one dose of interferon and/or ribavirin. The median time to treatment after being evaluated was 1.39 years. Of the 17 (35%) treated 6 patients had a sustained virologic response, but only 2.4% of the original number of patients were cured. Approximately one half of patients in an HIV-specialty clinic were evaluated for HCV therapy and 16% received treatment, but the median time to treatment from the time of HCV diagnosis was over 4 years. Further efforts to identify and to overcome barriers to HCV treatment are warranted.

0 0
 · 
0 Bookmarks
 · 
21 Views
  • Source
    Article: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008
    Keri N Althoff, Kate Buchacz, H Irene Hall, Jinbing Zhang, David B Hanna, Peter Rebeiro, Stephen J Gange, Richard D Moore, Mari M Kitahata, Kelly A Gebo, [......], Timothy R Sterling, Angela Cescon, Marina B Klein, Jennifer E Thorne, Heidi M Crane, Michael J Mugavero, Sonia Napravnik, Gregory D Kirk, Lisa P Jacobson, John T Brooks
    [show abstract] [hide abstract]
    ABSTRACT: Background: The U.S. National HIV/AIDS Strategy targets for 2015 include “increasing access to care and improving health outcomes for persons living with HIV in the United States” (PLWH-US). Objective: To demonstrate the utility of the NA-ACCORD (North American AIDS Cohort Collaboration on Research and Design) for monitoring trends in the HIV epidemic in the United States and to present trends in HIV treatment and related health outcomes. Design: Trends from annual cross-sectional analyses comparing patients from pooled, multicenter, prospective, clinical HIV cohort studies with PLWH-US, as reported to national surveillance systems in 40 states. Setting: U.S. HIV outpatient clinics. Patients: HIV-infected adults with 1 or more HIV RNA plasma viral load (HIV VL) or CD4 T-lymphocyte (CD4) cell count measured in any calendar year from 1 January 2000 to 31 December 2008. Measurements: Annual rates of antiretroviral therapy use, HIV VL, and CD4 cell count at death. Results: 45 529 HIV-infected persons received care in an NA-ACCORD–participating U.S. clinical cohort from 2000 to 2008. In 2008, the 26 030 NA-ACCORD participants in care and the 655 966 PLWH-US had qualitatively similar demographic characteristics. From 2000 to 2008, the proportion of participants prescribed highly active antiretroviral therapy increased by 9 percentage points to 83% (P < 0.001), whereas the proportion with suppressed HIV VL (≤2.7 log10 copies/mL) increased by 26 percentage points to 72% (P < 0.001). Median CD4 cell count at death more than tripled to 0.209 × 109 cells/L (P < 0.001). Limitation: The usual limitations of observational data apply. Conclusion: The NA-ACCORD is the largest cohort of HIV-infected adults in clinical care in the United States that is demographically similar to PLWH-US in 2008. From 2000 to 2008, increases were observed in the percentage of prescribed HAART, the percentage who achieved a suppressed HIV VL, and the median CD4 cell count at death.
    Annals of internal medicine 09/2012; 157(5):325. · 16.73 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

4 years
 
6 patients
 
covariates
 
Cox proportional hazards modeling
 
HCV
 
HCV diagnosis
 
HCV evaluation
 
HCV therapy
 
HCV treatment
 
HIV-specialty clinic
 
HIV/hepatitis C virus
 
January 1
 
median time
 
October 30
 
one dose
 
retrospective cohort study
 
ribavirin
 
Survival analysis
 
sustained virologic response
 
time trends
 

John D Scott